Neurological Health
Dementia & Parkinsonism
Growing evidence links chronic infections, including Lyme disease, to neurodegenerative conditions. Targeted oligonucleotide therapies may address the infectious drivers of cognitive decline and movement disorders.
Clinical Insight
Chronic infections like Borrelia burgdorferi can cross the blood-brain barrier, triggering neuroinflammation that mimics or accelerates dementia and Parkinson’s disease.
Emerging Research
Doxycycline in Parkinson's & Dementia
Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's. Characterized by progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc), current PD management is chiefly symptomatic — without modifying the underlying neuropathology. Prolonged use of anti-PD medications may be correlated with harmful effects such as dyskinesia and neuronal oxidative stress.
Drug Repurposing Strategy
Repurposing FDA-approved therapies with antioxidant and anti-inflammatory capacities may prevent PD neuropathology progression. Doxycycline has been shown to alleviate PD neuropathology by restraining neurodegeneration, neuroinflammation, oxidative stress, and endoplasmic reticulum (ER) stress — though its full molecular mechanism remains under investigation.
Doxycycline & Alzheimer's
Alzheimer's disease (AD) affects ~45 million people worldwide. With multiple failures of Aβ-centric therapies, multi-target approaches are needed. Among these, the antibiotic doxycycline — a second-generation tetracycline that crosses the blood–brain barrier easily with a safer clinical profile — has shown pleiotropic action against amyloidosis, neuroinflammation, and oxidative stress. Doxy gave compelling pre-clinical results in mouse models of AD against Aβ oligomers and neuroinflammation, strongly supporting its therapeutic potential.
Emerging Research
Intranasal Irbesartan for Alzheimer's
Alzheimer's disease involves a complex interplay between amyloid-β plaques, oxidative stress, neuroinflammation, and apoptosis — suggesting that multi-target therapies may be more effective than single-target treatments.
BBB Permeability
Angiotensin receptor blockers (ARBs) have shown protective effects against AD in hypertensive patients, but those with poor blood-brain barrier permeability exhibit limited efficacy. Intranasal delivery bypasses this barrier.
Irbesartan's Superior Profile
Among three ARBs and one ACEI tested, irbesartan showed the most robust neuroprotective effects — notably increasing p-AKT and HMOX1 levels in N2a and N2a-APPswe cell lines.
In Vivo Results
Intranasal irbesartan (40 mg/kg) administered to APP/PS1 mice for 10 weeks produced significant memory improvements, enhanced dendritic spine density, restored mitochondrial bioenergetics and BBB integrity, and reduced apoptotic markers.
These effects were accompanied by a marked reduction in oxidative stress and neuroinflammation. Overall, the results support intranasal irbesartan as a promising multi-target therapeutic strategy for AD, capable of modulating key pathological features including synaptic dysfunction, mitochondrial dysfunction, oxidative stress, apoptosis, and neuroinflammation.
Read the full study on ScienceDirect →Condition Profile
The infectious link to neurodegeneration
Dementia & Parkinsonism
Infectious triggers of cognitive and motor decline
Neuroinflammation driven by persistent infections can manifest as memory loss, confusion, tremors, rigidity, and bradykinesia. Addressing the underlying infectious burden may slow or reverse neurological deterioration.
Gene Targets
FAQ